H. Jensen

发表

Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study

L. Jacobsson, C. Divgi, R. Hultborn, 2009, Journal of Nuclear Medicine.

In Vitro Characterization of 211At-Labeled Antibody A33—a Potential Therapeutic Agent Against Metastatic Colorectal Carcinoma

H. Lundqvist, A. Sundin, V. Tolmachev, 2005 .

Biodistribution of 211At-labeled humanized monoclonal antibody A33.

H. Lundqvist, A. Sundin, V. Tolmachev, 2007, Cancer biotherapy & radiopharmaceuticals.

Towards elucidating the radiochemistry of astatine – Behavior in chloroform

C. Ekberg, P. Albertsson, H. Jensen, 2019, Scientific Reports.

Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.

B. Haraldsson, L. Jacobsson, R. Hultborn, 2009, Cancer biotherapy & radiopharmaceuticals.

Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer

P. Albertsson, L. Jacobsson, R. Hultborn, 2020, Translational oncology.

Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.

T. Ohlsson, T. Bäck, H. Jensen, 2014, Cancer biotherapy & radiopharmaceuticals.

Intraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities

H. Kahu, H. Andersson, J. Elgqvist, 2010, World journal of oncology.

Repeated Intraperitoneal α-Radioimmunotherapy of Ovarian Cancer in Mice

H. Kahu, R. Hultborn, H. Andersson, 2009, Journal of oncology.

Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.

L. Jacobsson, P. Bernhardt, R. Hultborn, 2006, International journal of radiation oncology, biology, physics.

Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.

L. Jacobsson, R. Hultborn, H. Andersson, 2006, Nuclear medicine and biology.

Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.

L. Jacobsson, R. Hultborn, H. Andersson, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.

L. Jacobsson, R. Hultborn, H. Andersson, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities.

H. Kahu, R. Hultborn, H. Andersson, 2009, Cancer biotherapy & radiopharmaceuticals.

In vitro evaluation of avidin antibody pretargeting using 211At‐labeled and biotinylated poly‐L‐lysine as effector molecule

H. Jensen, S. Lindegren, S. Frost, 2010, Cancer.

Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations

P. Dahm-Kähler, P. Albertsson, L. Jacobsson, 2019, The Journal of Nuclear Medicine.

Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the α-Camera Technique

P. Albertsson, L. Jacobsson, R. Hultborn, 2013, The Journal of Nuclear Medicine.

211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.

L. Jacobsson, C. Divgi, R. Hultborn, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200

C. Buchpiguel, P. Albertsson, R. Chammas, 2015, PloS one.

Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.

L. Jacobsson, P. Bernhardt, R. Hultborn, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.

P. Albertsson, L. Jacobsson, R. Hultborn, 2013, Cancer biotherapy & radiopharmaceuticals.

Multifunctional Clickable Reagents for Rapid Bioorthogonal Astatination and Radio‐Crosslinking

H. Jensen, S. Lindegren, M. Herth, 2019, ChemPlusChem.

Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with 211At-MX35-F(ab′)2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival

H. Kahu, P. Albertsson, T. Bäck, 2017, The Journal of Nuclear Medicine.

Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.

L. Jacobsson, A. Danielsson, R. Hultborn, 2007, International journal of radiation oncology, biology, physics.

Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields.

T. Bäck, H. Jensen, S. Lindegren, 2001, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure

P. Albertsson, T. Bäck, H. Jensen, 2020, Cancer biotherapy & radiopharmaceuticals.

In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.

L. Jacobsson, R. Hultborn, T. Bäck, 2011, Cancer biotherapy & radiopharmaceuticals.

Radioimmunotherapy With Astatine‐211 Using Chimeric Monoclonal Antibody U36 in Head and Neck Squamous Cell Carcinoma

V. Tolmachev, H. Jensen, M. Anniko, 2007, The Laryngoscope.

In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma

H. Lundqvist, V. Tolmachev, H. Jensen, 2005, European Journal of Nuclear Medicine and Molecular Imaging.

Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At.

B. Haraldsson, L. Jacobsson, R. Hultborn, 2012, Cancer biotherapy & radiopharmaceuticals.

Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy

A. Kjaer, P. Kempen, T. Bäck, 2021, Journal of Nanotheranostics.

Covalent core-radiolabeling of polymeric micelles with 125I/211At for theranostic radiotherapy

P. Kempen, T. Bäck, H. Jensen, 2022, Nanotheranostics.

Differential gene expression in human fibroblasts after alpha-particle emitter 211At compared with 60Co irradiation

K. Helou, A. Danielsson, S. Nemes, 2013, International journal of radiation biology.

Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.

P. Albertsson, V. Caveliers, T. Lahoutte, 2019, Molecular pharmaceutics.

Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials

P. Albertsson, T. Bäck, H. Jensen, 2015, Scientific Reports.

Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies.

P. Albertsson, H. Jensen, S. Lindegren, 2015, Cancer biotherapy & radiopharmaceuticals.

Short Communication Shelf-Life of e-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugates, Precursors for At Labeling of Antibodies

P. Albertsson, H. Jensen, S. Lindegren, 2015 .

Astatine-211 labeling: a study towards automatic production of astatinated antibodies

P. Albertsson, H. Jensen, S. Lindegren, 2014, Journal of Radioanalytical and Nuclear Chemistry.

Dif f erential gene expression in human fi broblasts after alpha-particle emitter 211 At compared with 60 Co irradiation

K. Helou, A. Danielsson, R. Hultborn, 2013 .

Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

A. Wu, P. Albertsson, K. Jennbacken, 2020, EJNMMI Research.

Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF

E. Blomquist, J. Carlsson, V. Tolmachev, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.

H. Lundqvist, P. Malmström, V. Tolmachev, 2006, Oncology reports.

Direct Procedure for the Production of 211At-Labeled Antibodies with an ε-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate

T. Bäck, J. Elgqvist, H. Jensen, 2008, Journal of Nuclear Medicine.

Labeled Antibodies with an e-Lysyl-3- (Trimethylstannyl)Benzamide Immunoconjugate

H. Jensen, S. Lindegren, S. Frost, 2008 .

A radio-high-performance liquid chromatography dual-flow cell gamma-detection system for on-line radiochemical purity and labeling efficiency determination.

L. Jacobsson, H. Jensen, S. Lindegren, 2014, Journal of chromatography. A.

Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.

L. Jacobsson, R. Hultborn, H. Andersson, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.

M. Ljungberg, P. Albertsson, L. Jacobsson, 2015, International journal of radiation oncology, biology, physics.

Alpha particle induced DNA damage and repair in normal cultured thyrocytes of different proliferation status.

H. Kahu, T. Bäck, H. Jensen, 2014, Mutation research.

N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides.

H. Jensen, S. Lindegren, Emma Aneheim, 2015, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211

T. Bäck, H. Jensen, S. Lindegren, 2023, Pharmaceuticals.

Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb

T. Bäck, H. Jensen, S. Lindegren, 2013, EJNMMI Research.

In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.

H. Lundqvist, A. Sundin, V. Tolmachev, 2005, Cancer Biotherapy and Radiopharmaceuticals.

Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.

P. Albertsson, F. Bruchertseifer, L. Jacobsson, 2012, Nuclear medicine and biology.

Direct Procedure for the Production of 211At-Labeled Antibodies with an ε-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate

T. Bäck, J. Elgqvist, H. Jensen, 2008, Journal of Nuclear Medicine.

Intraperitoneal Alpha-emitting Radio Immunotherapy with Astatine-211 in Relapsed Ovarian Cancer; Long-term Follow-up with Individual Absorbed Dose Estimations

Per Albertsson, Lars Jacobsson, Holger Jensen, 2019, Journal of Medical Imaging and Radiation Sciences.